Rejuvenation Technologies is a biotechnology company developing mRNA therapies to extend the healthspan by preventing and treating chronic age-related diseases. Their vision is to treat everyone, starting with a pipeline of therapies that target fatal diseases, including of the liver and lung. Co-founders John Ramunas and Glenn Markov developed fundamental technology at Stanford University in the lab of Helen Blau, on telomere extension and epigenetic reprogramming, and innovated further at Rejuvenation. Rejuvenation's mission is to extend the human healthspan.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/07/23 | $10,600,000 | Seed |
Asymmetry Ventures Longevity Tech Fund Merchant Adventures Shanda Group Y Combinator | undisclosed |
